IMVIONIX Inc. has officially debuted as a commercial-stage company by announcing its first major acquisition: the exclusive commercial rights to BEOVUE (brolucizumab-dbll) in the United States and Canada.
Big news indeed! Let’s get a look at this company.
Headquartered in Peachtree, Georgia, IMVIONIX is a privately-held ophthalmology biotechnology company specializing in retinal therapies.
- Worth noting: Its original launch date was actually in 2025 as part of a collaboration with two healthcare-focused investment firms: Caligan Partners LP and Velan Capital.
Its leadership team includes four former Alimera Sciences executives:
- Rick Eiswirth, co-founder, president, and CEO
- Jason Werner, chief operating officer
- Todd Wood, chief commercial officer
- Elliot Maltz, chief financial officer
Expand on its specialization.
Per IMVIONIX, the company “identifies, develops, and commercializes promising treatments that retina patients and physicians may need but cannot reach.”
In other words: It supports both earlier-stage programs and commercial-stage assets with “the potential to shape the future of retinal care.”
… and this BEOVU acquisition is part of that approach?
Indeed. The company refers to the purchase as its “first strategic transaction” in its mission to improve vision via retinal therapy advancement.
Tell me about it.
Developed by Novartis AG (and still a registered trademark of the company), BEOVU is a humanized single-chain antibody fragment (scFv) vascular endothelial growth factor (VEGF) inhibitor.
It is indicated for the treatment of:
- Neovascular (wet) age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
And this is already approved, right?
Correct. The intravitreal (IVT) injection was granted FDA approval in 2019 and Health Canada approval in 2020 (for wet AMD) and 2022 (for DME).
Can we get a look at its prescribing information?
So! What does this commercial rights deal entail?
Per the agreement, IMVIONIX will become the marketing authorization holder for BEOVU in the U.S. and Canada.
What this means: Essentially, BEOVU will be distributed for commercial use across North America under the IMVIONIX name.
- Outside this region: The product will still be sold by and under the Novartis name.
Any financial details to know about?
Nope, those weren’t disclosed.
Lastly, what’s the significance of the deal for IMVIONIX?
Aside from this being its first major move in the retinal space?
CEO Rick Eswirth emphasized that the acquisition reflects the company’s core mandate by “identifying therapies that align with our retina focused investment and commercialization platform.”